Biotech unicorn Moderna gambles $110M on a groundbreaking mRNA manufacturing facility, blueprints plant #2
Starting in a few weeks, Moderna will begin work on the biggest biotech manufacturing facility in the world dedicated to early stage R&D, producing its messenger RNA drugs for everything from tox work through Phase II studies. And with the first critical round of clinical data due to arrive in H1 2017, Moderna CEO Stephane Bancel says the biotech is already blueprinting another facility that may well dwarf the first $110 million manufacturing project.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.